Rigel Pharmaceuticals (RIGL) 10-Q2006 Q1 Quarterly report

Filed: 3 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Good

New words: accelerated, Add, adjustment, adopton, award, Axl, basket, bear, behavior, belief, biopharmaceutical, bond, Bulletin, cancellation, combination, combined, combining, commonly, constant, cumulative, destruction, dividend, drew, dry, EITF, employ, endpoint, equal, ESPP, expire, factor, FASB, feature, FIN, Force, forfeiture, FTB, gave, group, guidance, IgG, Immune, implied, inhaled, inhaler, insfrastructure, insignificant, interaction, interpretation, ITP, lesser, lower, mechanism, mediated, merged, methotrexate, modified, mouse, nonemployee, optionee, Platelet, play, powder, principle, publicly, Purpura, quoted, RA, refinement, refractory, reliance, remain, remained, remaining, remeasured, remeasurement, repayment, representative, repriced, requisite, reserve, reset, restructuring, Revised, run, SAB, SEC, segregated, shown, spleen, sponsorship, Standard, subsequent, subsequently, succeeding, suggest, Task, Thombocytopenia, thrombocytopenia, throughput, transition, transplant, Treasury, tyrosine, unamortized, undue, unrecognized, unvested, yield

Removed: assistance, broader, bulk, Commission, correct, correlation, couple, depository, dose, earn, establishing, estate, expansion, fifteen, forfeited, forward, fulfilled, halt, higher, HTS, improvement, inclusion, intended, investigate, ligase, light, measured, moving, nominate, onset, paper, park, payable, placebo, plasma, precluded, processed, profile, recording, revaluation, revalued, selected, substance, summarized, suspend, symptom, tolerated, top, treat, undesirable, vest, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RIGL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 15.1

May 1, 2006

The Board of Directors and Stockholders of Rigel Pharmaceuticals, Inc.

We are aware of the incorporation by reference in the following Registration Statements:

(1)		Form S-3 No. 333-129650, of Rigel Pharmaceuticals, Inc.
(2)		Form S-3 No. 333-119785, of Rigel Pharmaceuticals, Inc.
(3)		Form S-3 No. 333-112746, of Rigel Pharmaceuticals, Inc.
(4)		Form S-3 No. 333-111777, of Rigel Pharmaceuticals, Inc.
(5)		Form S-3 No. 333-106942, of Rigel Pharmaceuticals, Inc.
(6)		Form S-3 No. 333-105431, of Rigel Pharmaceuticals, Inc.
(7)		Form S-3 No. 333-87276 of Rigel Pharmaceuticals, Inc.
(8)		Form S-3 No. 333-74906 of Rigel Pharmaceuticals, Inc.
(9)		Form S-8 No. 333-125895, pertaining to the 2000 Equity Incentive Plan, 2000 Employee Stock Purchase Plan and 2000 Non-Employee Directors’ Stock Option Plan of Rigel Pharmaceuticals, Inc.
(10)		Form S-8 No. 333-111782, pertaining to the 2000 Equity Incentive Plan of Rigel Pharmaceuticals, Inc.
(11)		Form S-8 No. 333-107062, pertaining to the 2000 Employee Stock Purchase Plan of Rigel Pharmaceuticals, Inc.
(12)		Form S-8 No. 333-106532, pertaining to the 2000 Equity Incentive Plan, 2000 Employee Stock Purchase Plan and 2000 Non-Employee Directors’ Stock Option Plan of Rigel Pharmaceuticals, Inc.
(13)		Form S-8 No. 333-72492, pertaining to the 2001 Non-Officer Equity Incentive Plan of Rigel Pharmaceuticals, Inc.
(14)		Form S-8 No. 333-51184 pertaining to the 2000 Equity Incentive Plan, 2000 Employee Stock Purchase Plan and 2000 Non-Employee Directors’ Stock Option Plan of Rigel Pharmaceuticals, Inc.

		in each case related to the sale of shares of common stock, and in the related prospectuses, as applicable, contained in such Registration Statements of our report dated April 24, 2006, relating to the unaudited condensed interim financial statements of Rigel Pharmaceuticals, Inc. that are included in its Form 10-Q for the quarter ended March 31, 2006.

		Pursuant to Rule 436(c) of the Securities Act of 1933, our report is not a part of the registration statements prepared or certified by accountants within the meaning of section 7 or 11 of the Securities Act of 1933, as amended.

	/s/ Ernst & Young LLP

Palo Alto, California
May 1, 2006

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.